Losmapimod

Drug Profile

Losmapimod

Alternative Names: 856553; GS856553; GSK 856553; GW 856553; GW856553X

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Cardiovascular therapies; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes
  • Phase II Chronic obstructive pulmonary disease; Focal segmental glomerulosclerosis
  • Phase I Inflammation
  • Discontinued Atherosclerosis; Dyslipidaemias; Major depressive disorder; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 13 May 2016 Efficacy data from the phase III EVOLUTION trial in Chronic obstructive pulmonary disease presented at the Conference of the American Thoracic Society (ATS-2016)
  • 01 May 2016 GlaxoSmithKline completes a phase II trial in Focal segmental glomerulosclerosis in USA and Canada (NCT02000440)
  • 07 Sep 2015 Phase-II development for Chronic obstructive pulmonary disease is ongoing in Argentina and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top